| User's Publication |
|
21621
Tokito F, Kiyofuji M, Choi H, Nishikawa M, Takezawa T, Sakai Y.
Modulation of hepatic cellular tight junctions via coculture with cholangiocytes enables non-destructive bile recovery.
J Biosci Bioeng
2024
PubMed ID: 38413317
DOI: 10.1016/j.jbiosc.2024.01.017
|
|
21815
Noronha KJ, Lucas KN, Paradkar S, Edmonds J, Friedman S, Murray MA, Liu S, Sajed DP, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram RK, Shuch B, Vasquez JC, Bindra RS.
NAPRT silencing in FH-deficient renal cell carcinoma confers therapeutic vulnerabilities via NAD+ depletion.
Mol Cancer Res
2024
PubMed ID: 38949523
DOI: 10.1158/1541-7786.MCR-23-1003
|
|
22026
Changphasuk P, Inpad C, Horpaopan S, Khunchai S, Phimsen S, Surangkul D, Janvilisri T, Silsirivanit A, Kaewkong W.
SRPK Inhibitors Reduce the Phosphorylation and Translocation of SR Protein Splicing Factors, thereby Correcting BIN1, MCL-1 and BCL2 Splicing Errors and Enabling Apoptosis of Cholangiocarcinoma Cells.
Front Biosci (Schol Ed)
2024
PubMed ID: 39344395
DOI: 10.31083/j.fbs1603017
|
|
22143
Shinada M, Takahashi M, Igarashi C, Matsumoto H, Hihara F, Tachibana T, Oikawa M, Suzuki H, Zhang MR, Higashi T, Kurihara H, Yoshii Y, Doi Y.
64Cu2+ Complexes of Tripodal Amine Ligands' In Vivo Tumor and Liver Uptakes and Intracellular Cu Distribution in the Extrahepatic Bile Duct Carcinoma Cell Line TFK-1: A Basic Comparative Study.
Pharmaceuticals (Basel)
2024
17(7)
PubMed ID: 39065671
DOI: 10.3390/ph17070820
|
|
19596
Miaki UZU, Toshiaki TAKEZAWA
Novel Cell Culture Technology to Harvest Hepatic Metabolites Accumulated in the Bile Canaliculus-like Structures between HepG2-NIAS Cells Utilizing Crosstalk with TFK-1 Cells
Nano Biomedicine
2023
15(2):75-87
DOI: 10.11344/nano.15.75
|
|
19739
Yogo A, Masui T, Takaishi S, Masuo K, Chen R, Kasai Y, Nagai K, Anazawa T, Watanabe S, Sakamoto S, Watanabe A, Inagaki R, Nakagawa MM, Ogawa S, Seno H, Uemoto S, Hatano E.
Inhibition of dopamine receptor D1 signaling promotes human bile duct cancer progression via WNT signaling
Cancer Sci
2023
114(4):1324-1336
PubMed ID: 36441110
DOI: 10.1111/cas.15676
|
|
20980
Takahashi M, Tsuchikawa T, Hiwasa T, Nakamura T, Hontani K, Kushibiki T, Inoko K, Takano H, Hatanaka Y, Matsushita K, Matsubara H, Hoshino T, Ohtsuka M, Shimada H, Tanaka K, Nakanishi Y, Asano T, Noji T, Okamura K, Shichinohe T, Hirano S.
Identification of antibody against wingless‑type MMTV integration site family member 7B as a biliary cancer tumor marker.
Oncol Rep
2023
49(2)
PubMed ID: 36562381
DOI: 10.3892/or.2022.8471
|
|
21109
Oba M, Nakanishi Y, Mitsuhashi T, Sasaki K, Hatanaka KC, Sasaki M, Nange A, Okumura A, Hayashi M, Yoshida Y, Nitta T, Ueno T, Yamada T, Ono M, Kuwabara S, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Tanaka K, Takayama K, Hatanaka Y, Hirano S.
CCR7 Mediates Cell Invasion and Migration in Extrahepatic Cholangiocarcinoma by Inducing Epithelial-Mesenchymal Transition.
Cancers (Basel)
2023
15(6)
PubMed ID: 36980764
DOI: 10.3390/cancers15061878
|
|
21324
Liu D, Shi Y, Chen H, Nisar MA, Jabara N, Langwinski N, Mattson S, Nagaoka K, Bai X, Lu S, Huang CK.
Molecular profiling reveals potential targets in cholangiocarcinoma.
World J Gastroenterol
2023
29(25):4053-4071
PubMed ID: 37476584
DOI: 10.3748/wjg.v29.i25.4053
|
|
17715
Zhang L, Ma D, Li F, Qiu G, Sun D, Zeng Z.
Lnc-PKD2-2-3/miR-328/GPAM ceRNA Network Induces Cholangiocarcinoma Proliferation, Invasion and 5-FU Chemoresistance
Front Oncol
2022
12:871281
PubMed ID: 35965521
DOI: 10.3389/fonc.2022.871281
|
|
18104
Ueno G, Iwagami Y, Kobayashi S, Mitsufuji S, Yamada D, Tomimaru Y, Akita H, Asaoka T, Noda T, Gotoh K, Mori M, Doki Y, Eguchi H.
ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer
Ann Surg Oncol
2022
29(5):2899-2909
PubMed ID: 34994902
DOI: 10.1245/s10434-021-11152-1
|
|
16279
Seo HR, Nam AR, Bang JH, Oh KS, Kim JM, Yoon J, Kim TY, Oh DY.
Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
Cancer Res Treat
2022
Aug 6
PubMed ID: 34352995
DOI: 10.4143/crt.2021.473
|
|
20697
Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K.
Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Toxicol In Vitro
2022
105385
PubMed ID: 35568131
DOI: 10.1016/j.tiv.2022.105385
|
|
21043
Wu WS, Chen RF, Cheng CC, Wei JL, Lin CF, You RI, Chen YC, Lee MC, Chen YC.
Suppressing of Src-Hic-5-JNK-AKT Signaling Reduced GAPDH Expression for Preventing the Progression of HuCCT1 Cholangiocarcinoma.
Pharmaceutics
2022
14(12)
PubMed ID: 36559193
DOI: 10.3390/pharmaceutics14122698
|
|
13485
Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M, Sakamoto N.
Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes
Cancer Sci
2021
112(2):828-838
PubMed ID: 33345417
DOI: 10.1111/cas.14780
|
|
20163
Nam AR, Yoon J, Jin MH, Bang JH, Oh KS, Seo HR, Kim JM, Kim TY, Oh DY.
ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.
Cancer Lett
2021
516:38-47
PubMed ID: 34082024
DOI: 10.1016/j.canlet.2021.05.029
|
|
14929
Yokota K, Serada S, Tsujii S, Toya K, Takahashi T, Matsunaga T, Fujimoto M, Uemura S, Namikawa T, Murakami I, Kobayashi S, Eguchi H, Doki Y, Hanazaki K, Naka T.
Anti-glypican-1 antibody-drug conjugate as potential therapy against tumor cells and tumor vasculature for glypican-1 positive cholangiocarcinoma
Mol Cancer Ther
2021
molcanther.0015.2021
PubMed ID: 34224365
DOI: 10.1158/1535-7163.MCT-21-0015
|
|
16118
Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Yan I, Aso K, Fujii S, Patel T, Haneda M
Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth
FEBS Open Bio
2021
11(12):3276-329
PubMed ID: 34510808
DOI: 10.1002/2211-5463.13294
|
|
12014
Somchai P, Phongkitkarun K, Kueanjinda P, Jamnongsong S, Vaeteewoottacharn K, Luvira V, Okada S, Jirawatnotai S, Sampattavanich S.
Novel Analytical Platform For Robust Identification of Cell Migration Inhibitors.
Sci Rep
2020
PubMed ID: 31969633
DOI: 10.1038/s41598-020-57806-0
|
|
12036
San TT, Khaenam P, Prachayasittikul V, Sripa B, Kunkeaw N, Chan-On W.
Curcumin enhances chemotherapeutic effects and suppresses ANGPTL4 in anoikis-resistant cholangiocarcinoma cells.
Heliyon
2020
PubMed ID: 32051864
DOI: 10.1016/j.heliyon.2020.e03255
|
|
12044
Fukuda Y, Asaoka T, Eguchi H, Yokota Y, Kubo M, Kinoshita M, Urakawa S, Iwagami Y, Tomimaru Y, Akita H, Noda T, Gotoh K, Kobayashi S, Hirata M, Wada H, Mori M, Doki Y.
Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma.
Cancer Sci.
2020
PubMed ID: 31799781
DOI: 10.1111/cas.14267
|
|
12163
Aman Tedasen, Araya Khoka, Siribhorn Madla, Somchai Sriwiriyajan, Potchanapond Graidist
Anticancer effects of piperine-free Piper nigrum extract on cholangiocarcinoma cell lines
Pharmacognosy Magazine
2020
DOI: 10.4103/pm.pm_288_19
|
|
13336
Pan YR, Wu CE, Yeh CN.
ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.
Biomolecules
2020
PubMed ID: 33182492
DOI: 10.3390/biom10111529
|
|
13552
Nam AR, Jin MH, Bang JH, Oh KS, Seo HR, Oh DY, Bang YJ.
Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
Cancer Res Treat
2020
52(3):945-956
PubMed ID: 32311864
DOI: 10.4143/crt.2020.080
|
|
13579
Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Uson PLS, Nagalo BM, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ.
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer
Cancer Chemother Pharmacol
2020
85(6):1063-1078
PubMed ID: 32440762
DOI: 10.1007/s00280-020-04079-z
|
|
20122
Hendaoui I, Lahmar A, Campo L, Mebarki S, Bichet S, Hess D, Degen M, Kchir N, Charrada-Ben Farhat L, Hefaiedh R, Ruiz C, Terracciano LM, Tucker RP, Hendaoui L, Chiquet-Ehrismann R.
Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers.
Front Immunol
2020
11:630139
PubMed ID: 33692777
DOI: 10.3389/fimmu.2020.630139
|
|
11476
Wei K, Li M, Zöller M, Wang M, Mehrabi A, Hoffmann K.
Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
Cell Death Dis
2019
PubMed ID: 30850583
DOI: 10.1038/s41419-019-1460-1
|
|
4244
Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ.
Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Cancer Res Treat
2019
51(3):1167-1179
PubMed ID: 30514066
DOI: 10.4143/crt.2018.526
|
|
4245
Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ.
Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Cancer Res Treat
2019
51(3):886-900
PubMed ID: 30282449
DOI: 10.4143/crt.2018.375
|
|
11552
Yu J, Shi L, Shen X, Zhao Y.
UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals.
Biochem. Pharmacol.
2019
PubMed ID: 31085159
DOI: 10.1016/j.bcp.2019.05.017
|
|
14815
Song IH, Jeong MS, Hong HJ, Shin JI, Park YS, Woo SK, Moon BS, Kim KI, Lee YJ, Kang JH, Lee TS.
Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model
Clin Cancer Res
2019
25(20):6148-6159
PubMed ID: 31337646
DOI: 10.1158/1078-0432.CCR-19-1157
|
|
10816
Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M.
Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition.
Oncotarget
2018
9:16400-16417
PubMed ID: 29662654
DOI: 10.18632/oncotarget.24711
|
|
10834
Kawamoto M, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Kawabe K, Onishi H, Nakamura M, Morisaki T.
Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma.
Anticancer Res.
2018
38:2739-2748
PubMed ID: 29715094
DOI: 10.21873/anticanres.12516
|
|
10838
Huang CK, Iwagami Y, Zou J, Casulli S, Lu S, Nagaoka K, Ji C, Ogawa K, Cao KY, Gao JS, Carlson RI, Wands JR.
Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.
Cancer Lett.
2018
429:1-10
PubMed ID: 29733964
DOI: 10.1016/j.canlet.2018.04.041
|
|
11090
Ishigami K, Nosho K, Koide H, Kanno S, Mitsuhashi K, Igarashi H, Shitani M, Motoya M, Kimura Y, Hasegawa T, Kaneto H, Takemasa I, Suzuki H, Nakase H.
MicroRNA-31 reflects IL-6 expression in cancer tissue and is related with poor prognosis in bile duct cancer.
Carcinogenesis
2018
39(9):1127-1134
PubMed ID: 29860474
DOI: 10.1093/carcin/bgy075
|
|
11166
Okumura Y, Noda T, Eguchi H, Sakamoto T, Iwagami Y, Yamada D, Asaoka T, Wada H, Kawamoto K, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M.
Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Ann. Surg. Oncol.
2018
25(12):3728-3737
PubMed ID: 30105440
DOI: 10.1245/s10434-018-6670-8
|
|
4339
Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M.
FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.
Cancer Sci.
2018
PubMed ID: 30302867
DOI: 10.1111/cas.13829
|
|
4360
Ohashi T, Eguchi H, Kawamoto K, Konno M, Asai A, Colvin H, Ueda Y, Takaoka H, Iwagami Y, Yamada D, Asaoka T, Noda T, Wada H, Gotoh K, Kobayashi S, Koseki J, Satoh T, Ogawa K, Doki Y, Mori M, Ishii H.
Mitochondrial pyruvate carrier modulates the epithelial-mesenchymal transition in cholangiocarcinoma.
Oncol. Rep.
2018
39(3):1276-1282
PubMed ID: 29286150
DOI: 10.3892/or.2017.6172
|
|
14913
Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.
Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
Dis Model Mech
2018
11(8):dmm03305
PubMed ID: 29666220
DOI: 10.1242/dmm.033050
|
|
10312
Račkauskas R, Zhou D, Ūselis S, Strupas K, Herr I, Schemmer P.
Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.
Oncol. Rep.
2017
37:3660-3666
PubMed ID: 28498473
DOI: 10.3892/or.2017.5622
|
|
4099
A novel photodynamic therapy-based drug delivery system layered on a stent for treating cholangiocarcinoma
Biomedical Microdevices
2017
20:3
PubMed ID: 29164403
DOI: 10.1007/s10544-017-0249-1
|
|
5767
Ito M, Sun S, Fukuhara T, Suzuki R, Tamai M, Yamauchi T, Nakashima K, Tagawa Y, Okazaki S, Matsuura Y, Wakita T, Suzuki T.
Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation.
Oncotarget
2017
8(33):53899-53915
PubMed ID: 28903311
DOI: 10.18632/oncotarget.19108
|
|
14252
Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.
Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification
Int J Oncol
2017
50(1):129-140.
PubMed ID: 27922671
DOI: 10.3892/ijo.2016.3786
|
|
14528
Yagai T, Matsui S, Harada K, Inagaki FF, Saijou E, Miura Y, Nakanuma Y, Miyajima A, Tanaka M.
Expression and localization of sterile alpha motif domain containing 5 is associated with cell type and malignancy of biliary tree
PLoS One
2017
12(4):e0175355
PubMed ID: 28388653
DOI: 10.1371/journal.pone.0175355
|
|
14652
Tsukagoshi M, Araki K, Yokobori T, Altan B, Suzuki H, Kubo N, Watanabe A, Ishii N, Hosouchi Y, Nishiyama M, Shirabe K, Kuwano H.
Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins
Oncotarget
2017
8(26):42159-42172
PubMed ID: 28178675
DOI: 10.18632/oncotarget.15020
|
|
9515
Sakamoto T, Kobayashi S, Yamada D, Nagano H, Tomokuni A, Tomimaru Y, Noda T, Gotoh K, Asaoka T, Wada H, Kawamoto K, Marubashi S, Eguchi H, Doki Y, Mori M.
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
PLoS ONE
2016
11:e0145985
PubMed ID: 26726879
DOI: 10.1371/journal.pone.0145985
|
|
9668
Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Src as a Therapeutic Target in Biliary Tract Cancer.
Mol. Cancer Ther.
2016
15:1515-24
PubMed ID: 27196758
DOI: 10.1158/1535-7163.MCT-16-0013
|
|
9700
Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, Kalthoff H, Egberts JH, Braun F.
Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.
BMC Cancer
2016
16:322
PubMed ID: 27206490
DOI: 10.1186/s12885-016-2360-8
|
|
3735
Saha SK et al
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Cancer Discov
2016
6(7):727-39
PubMed ID: 27231123
DOI: 10.1158/2159-8290.CD-15-1442
|
|
14138
Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Therapeutic implication of HER2 in advanced biliary tract cancer
Oncotarget
2016
7(36):58007-58021
PubMed ID: 27517322
DOI: 10.18632/oncotarget.11157
|
|
7201
Fujimori T, Kato K, Fujihara S, Iwama H, Yamashita T, Kobayashi K, Kamada H, Morishita A, Kobara H, Mori H, Okano K, Suzuki Y, Masaki T.
Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies.
Oncol. Rep.
2015
34:2987-96
PubMed ID: 26398221
DOI: 10.3892/or.2015.4284
|
|
7429
Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A.
DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.
PLoS ONE
2015
10:e0120545
PubMed ID: 25799509
DOI: 10.1371/journal.pone.0120545
|
|
4891
Peraldo Neia C, Cavalloni G, Balsamo A, Venesio T, Napoli F, Sassi F, Martin V, Frattini M, Aglietta M, Leone F.
Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR.
Genes Chromosomes Cancer
2014
53(12):1033-40
PubMed ID: 25231053
DOI: 10.1002/gcc.22212
|
|
14393
Nakagawa S, Sakamoto Y, Okabe H, Hayashi H, Hashimoto D, Yokoyama N, Tokunaga R, Sakamoto K, Kuroki H, Mima K, Beppu T, Baba H.
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells
Oncol Rep
2014
31(2):983-8
PubMed ID: 24337160
DOI: 10.3892/or.2013.2922
|
|
14930
Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A.
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater
Int J Oncol
2014
44(4):1139-45
PubMed ID: 24481592
DOI: 10.3892/ijo.2014.2282
|
|
3722
Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.
Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
Cancer Sci
2012
103(2):252-61
PubMed ID: 22044563
DOI: 10.1111/j.1349-7006.2011.02138.x
|
|
15724
Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H.
E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma
Br J Cancer
2011
105(12):1885-93
PubMed ID: 22068819
DOI: 10.1038/bjc.2011.452
|
|
19310
Takayama Y, Kokuryo T, Yokoyama Y, Ito S, Nagino M, Hamaguchi M, Senga T.
Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis
Cancer Lett
2010
296(1):27-34
PubMed ID: 20381954
DOI: 10.1016/j.canlet.2010.03.011
|
|
18737
Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, Inagaki F.
Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues
J Proteome Res
2009
8(8):4092-103
PubMed ID: 19569727
DOI: 10.1021/pr900468k
|
|
15602
Guleng B, Tateishi K, Ohta M, Asaoka Y, Jazag A, Lin LJ, Tanaka Y, Tada M, Seto M, Kanai F, Kawabe T, Omata M.
Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity
J Gastroenterol
2006
41(12):1238-9
PubMed ID: 17287906
DOI: 10.1007/s00535-006-1955-2
|
Back
Top
CELL BANK Website
